Correlation Between Eterna Therapeutics and Sonnet Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eterna Therapeutics and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eterna Therapeutics and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eterna Therapeutics and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Eterna Therapeutics and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eterna Therapeutics with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eterna Therapeutics and Sonnet Biotherapeutics.

Diversification Opportunities for Eterna Therapeutics and Sonnet Biotherapeutics

0.86
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Eterna and Sonnet is 0.86. Overlapping area represents the amount of risk that can be diversified away by holding Eterna Therapeutics and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Eterna Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eterna Therapeutics are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Eterna Therapeutics i.e., Eterna Therapeutics and Sonnet Biotherapeutics go up and down completely randomly.

Pair Corralation between Eterna Therapeutics and Sonnet Biotherapeutics

Given the investment horizon of 90 days Eterna Therapeutics is expected to generate 1.6 times more return on investment than Sonnet Biotherapeutics. However, Eterna Therapeutics is 1.6 times more volatile than Sonnet Biotherapeutics Holdings. It trades about -0.09 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about -0.29 per unit of risk. If you would invest  99.00  in Eterna Therapeutics on October 21, 2024 and sell it today you would lose (57.00) from holding Eterna Therapeutics or give up 57.58% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Eterna Therapeutics  vs.  Sonnet Biotherapeutics Holding

 Performance 
       Timeline  
Eterna Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eterna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Sonnet Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Eterna Therapeutics and Sonnet Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eterna Therapeutics and Sonnet Biotherapeutics

The main advantage of trading using opposite Eterna Therapeutics and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eterna Therapeutics position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.
The idea behind Eterna Therapeutics and Sonnet Biotherapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bonds Directory
Find actively traded corporate debentures issued by US companies